Seminars in Oncology Nursing
Volume 23, Issue 3 , Pages 225-231 , August 2007

Clinical Dilemma: Dyspnea

  • Maureen E. O’Rourke

      Affiliations

    • Corresponding Author InformationAddress correspondence to Maureen E. O’Rourke, RN, PhD, 3545 Summerfield Lane, Winston-Salem, NC 27106

References 

  1. Williams CM. Dyspnea. Cancer J. 2006;12:365–373
  2. Oncology Nursing Society. ONS levels of evidence. Available at. http://onsopcontent.ons.org/toolkits/evidence/Process/levels.shtml (accessed November 25, 2006).
  3. Esper P, Heidrich D. Symptom clusters in advanced illness. Semin Oncol Nurs. 2005;21:20–28
  4. Reddy SK, Elsayem A, Talukdar R. Pain management and symptom control. In:  Kantarjian HM,  Wolff RA,  Koller CA editor. MD Anderson manual of medical oncology. New York, NY: McGraw-Hill; 2006;p. 1067–1068
  5. Cullen DL, Rodak B. Clinical utility of measures of breathlessness. Resp Care. 2002;47:986–993
  6. Escalante CP, Martin CG, Elting LS, et al. Dyspnea in cancer patients: etiology, resource utilization and survival–implications in a managed care world. Cancer. 1996;78:1314–1319
  7. Buera E, Sweeney C, Willey J, et al. A randomized controlled trial of supplemental oxygen versus air in cancer patients with dyspnea. Palliat Med. 2003;17:659–663
  8. Kvale PA, Simoff M, Prakash UBS. Palliative care. Chest. 2003;123:284S–311S
  9. Swinburn CR, Mould H, Stone TN, et al. Symptomatic benefit of supplemental oxygen in hypoxemic patient with chronic lung disease. Am Rev Resp Dis. 1991;143:913–915
  10. Bruera E, de Stoultz N, Velasco-Leiva A, et al. Effects of oxygen on dyspnoea in hypoxaemic terminal-cancer patients. Lancet. 1993;342:13–14
  11. Wickham RS. Managing dyspnea in cancer patients. Dev Support Cancer Care. 1998;2:33–40
  12. Zebraksi S, Kochenash S, Raffa R. Lung opioid receptors: pharmacology and possible target for nebulized morphine in dyspnea. Life Sci. 2000;66:2221–2231
  13. Jennings AL, Davies AN, Higgins JPT, et al. Opioids for the palliation of breathlessness in terminal illness. Cochrane Database Syst Rev 2001, Issue 3. Art. No. CD002066. DOI 10.1002/14651858. CD002066. Available at: http://www/mrw.interscience.wiley.com/Cochrane/clsyrev/articles/SC002066/frame.html (accessed November 22, 2006).
  14. Mazzocato C, Buclin T, Rapin CH. The effects of morphine on dyspnea and ventilatory function in elderly patients with advanced cancer: a randomized double-blind controlled trial. Ann Oncol. 1999;10:1511–1514
  15. Allard P, Lamontagne C, Bernard P, et al. How effective are supplementary doses of opioids for dyspnea in terminally ill cancer patients? (A randomized continuous sequential clinical trial). J Pain Symptom Manage. 1999;17:256–265
  16. Akiyama Y, Nishimur M, Kobayashi S, et al. Effects of naloxone on the sensation of dyspnea during acute respiratory stress in normal adults. J Applied Physiol. 1993;74:590–595
  17. Banzett RB, Mulnier HE, Murphy K, et al. Breathlessness in humans activates insular cortex. Neuroreport. 2000;11:217–220
  18. Coyne P, Viswanathan R, Smith T. Nebulized fentanyl citrate improves patients’ perception of breathing, respiratory rate, and oxygen saturation in dyspnea. J Pain Symptom Manage. 2002;23:157–160
  19. Sarhill N, Walsh D, Khawam E, et al. Nebulized hydromorphone for dyspnea in hospice care of advanced cancer. Am J Hosp Palliat Care. 2002;17:389–391
  20. Jennings A, Davies AM, Higgins J, et al. A systematic review of the use of opioids in the management of dyspnea. Thorax. 2002;57:939–944
  21. Ferrarresi V. Inhaled opioids for the treatment of dyspnea. Am J Health Syst Pharm. 2005;62:319–320
  22. Benitez-Rosario MA, Feria M. Oral transmucosal fentanyl citrate in the management of dyspnea crises in cancer patients. J Pain Symptom Manage. 2005;30:395–397
  23. Aranoff GM, Brennan MJ, Pritchard DD, et al. Evidence-based oral transmucosal fentanyl citrate (OTFC) dosing guidelines. Pain Med. 2005;6:305–314
  24. Dudgeon D, Lertzman M, Askew G. Physiologic changes and clinical correlations in dyspnea in cancer outpatients. J Pain Symptom Manage. 2001;21:373–379
  25. Mitchell-Heggs P, Murphy K, Minty K, et al. Diazepam in the treatment of dyspnea in the pink puffer syndrome. Q J Med. 1980;193:9–20
  26. Navigante A, Cerchietti ACA, Castro M, et al. Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced cancer. J Pain Symptom Manage. 2006;31:38–47
  27. Ash-Bernal R, Browner I, Erlich R. Early detection and successful treatment of drug-induced pneumonitis with corticosteroids. Cancer Invest. 2002;20:876–879
  28. Bianco S, Vaghi A, Robushi M, et al. Prevention of exercise-induced bronchospasm by inhaled furosemide. Lancet. 1988;2:252–255
  29. Stone P, Kurowska A, Schwartzstein RM. Nebulized furosemide for dyspnea. Palliat Med. 1994;8:258
  30. Kohara H, Ueoka H, Aoe K, et al. Effect of nebulized furosemide in terminally ill cancer patients with dyspnea. J Pain Symptom Manage. 2003;26:962–967
  31. Moosavi SH, Binks AP, Lansing RW, et al. Effect of furosemide on air hunger induced in healthy humans. Respir Physiol Neurobiol. 2007;156:1–8
  32. Shimoyama N, Shimoyama M. Nebulized furosemide as a novel treatment for dyspnea in terminal cancer patients. J Pain Symptom Manage. 2002;23:73–76
  33. Bredin M, Corner J, Krishnasamy M, et al. Multicentre randomized controlled trial of nursing intervention for breathlessness in patients with lung cancer. Br Med J. 1999;318:901–905
  34. Hatley J, Laurene V, Scott A, et al. Breathlessness clinics within specialist palliative care settings can improve the quality of life and functional capacity of patients with lung cancer. Palliat Med. 2003;17:410–417
  35. Liss HP, Grant BJ. The effect of nasal flow on breathlessness in patients with chronic obstructive pulmonary disease. Am Rev Resp Dis. 1998;137:1285–1288
  36. Schwartzstein RM, Lahive K, Pope A, et al. Cold facial stimulation reduces breathlessness induced in normal subjects. Am Rev Respir Dis. 1987;136:58–61
  37. Wu HS, Wu Sc, Lin JG, et al. Effectiveness of acupressure in improving dyspnoea in chronic obstructive pulmonary disease. J Adv Nurs. 2004;45:252–259
  38. Maa S, Gauthier D, Turner M. Acupressure as an adjunct to a pulmonary rehabilitation program. J Cardiopulm Rehab. 1997;17:268–176
  39. Vickers A, Feinstein M, Deng G, et al. Acupuncture for dyspnea in advanced cancer: A randomized placebo-controlled pilot trial [ISRCTN89462491]. BMC Palliat Care. 2005;18:4–5
  40. Lewith GT, Prescott P, Davis CL. Can a standardized acupuncture technique palliate disabling breathlessness: a single-blind placebo crossover study. Chest. 2004;125:1783–1790
  41. Neuenschwander H, Molto A, Bianchi M. External nasal dilator strips (ENDS) may improve breathlessness in cancer patients. Support Care Cancer. 2006;14:386–388

PII: S0749-2081(07)00057-5

doi: 10.1016/j.soncn.2007.05.007

Seminars in Oncology Nursing
Volume 23, Issue 3 , Pages 225-231 , August 2007

Article Tools